Australian-based biopharmaceutical company Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has delivered strong global sales growth for its over-the-counter immune supplement Travelan® in the September 2024 quarter.
Increase in global sales
The product, designed to target pathogenic bacteria and toxins in the gastrointestinal tract, generated A$1.5 million in global sales during the quarter, a 13% increase on the previous quarter.
In Australia, sales of Travelan® reached A$1.0 million for the September quarter, representing a 3% rise compared to the June 2024 quarter.
The company has expanded its distribution network, securing placements in nine additional pharmacy banner groups across the country.
North American sales experienced significant growth, increasing by 48% to A$500,000 for the quarter, up from A$300,000 in the previous period.
Immuron also achieved its highest monthly sales on Amazon (NASDAQ:AMZN) in the US and expanded distribution to 10 pharmacy and grocery retailers in Canada.
Momentum in key markets
Immuron continues to see positive momentum for Travelan® as it expands its global footprint with sustained demand in key markets.
Chief commercial officer Flavio Palumbo said: “As anticipated, we are achieving strong growth in North America with continued growth in Australia.
“We have secured core ranging in another nine pharmacy banner groups in Australia.
“We had our strongest monthly sales on amazon.com in the US. We now have distribution in ten pharmacy/grocery retailers in Canada.”
More news from Immuron in the September quarter:
Watch: Just the Facts: Immuron's favourable FDA feedback
Read: Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529
Read: Immuron nets A$3.5 million in funding from US Department of Defense for Travelan® research
Read: Immuron "trading at substantial discount to valuation": Pitt Street Research